Compare 3M Company (MMM) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
3M Company vs Moderna, Inc. — how do they compare? 3M Company trades at $164.59 (market cap $86.39B), while Moderna, Inc. trades at $136.28 (market cap $56.02B). The key difference: 3M Company is the larger of the two by market cap, and 3M Company pays a 1.86% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MMM | MRNA | |
|---|---|---|
Market Cap | $86.39B | $56.02B |
Sector | Industrials | Health |
52-Week High | $183.79 | $174.38 |
52-Week Low | $141.10 | $22.36 |
Enterprise Value | $95.61B | $52.17B |
Dividend Yield | 1.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
3M (MMM) trades at $167.52, down 0.62% on the day, with a bearish technical signal but strong recent earnings beats. The company shows solid profitability with an 11.9% net income margin and 82.77% ROE, though revenue has declined from 2022 peaks. Positive news highlights strength in transportation, electronics, and safety segments, while consumer demand remains soft.
The stock offers a balanced outlook: analyst consensus is a Buy with a $173 price target, but high debt and cost pressures pose risks. Earnings momentum from industrial growth supports upside, yet valuation multiples like a 29.75 P/E suggest limited margin for error. Investors should weigh robust fundamentals against macroeconomic and segment-specific headwinds.
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
